Pulse Biosciences (PLSE) said Thursday that preliminary data from its first-in-human study of nanosecond pulsed field ablation technology showed reduction in benign thyroid nodule sizes by over 50% on average.
The pulses did not leave any residual fibrosis or scarring and symptoms improved within the first month, according to the company.
The company's shares fell 3% in recent trading.
Price: 17.18, Change: -0.54, Percent Change: -3.08
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。